<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673164</url>
  </required_header>
  <id_info>
    <org_study_id>SCIENCE</org_study_id>
    <nct_id>NCT02673164</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease</brief_title>
  <acronym>SCIENCE</acronym>
  <official_title>Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease - SCIENCE A European Multi-Centre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JKastrup</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the SCIENCE study is, in an international multicentre double-blind&#xD;
      placebo-controlled study, to investigate efficacy of direct intra-myocardial injection of 100&#xD;
      mio. allogeneic Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASCs) in&#xD;
      patients with reduced left ventricular Ejection Fraction (EF) (≤45%) and heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the SCIENCE study is, in an international multicentre double-blind&#xD;
      placebo-controlled study, to investigate efficacy of direct intra-myocardial injection of 100&#xD;
      mio. allogeneic Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASCs) in&#xD;
      patients with reduced left ventricular EF (≤45%) and heart failure.&#xD;
&#xD;
      The primary objective is to investigate the regenerative capacity of direct intra-myocardial&#xD;
      injection of 100 mio. allogeneic CSCC_ASCs in patients with reduced left ventricular EF&#xD;
      (≤45%) and heart failure in a double-blind placebo-controlled design.&#xD;
&#xD;
      A total of 138 patients with will be enrolled in the study and treated in a 2:1 randomization&#xD;
      with either CSCC_ASC or placebo (saline).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricle end-systolic volume (LVESV)</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint is change in left ventricle end-systolic volume (LVESV) from baseline to 6 months follow-up measured by ECHO, MR and CT between CSCC_ASC and placebo treated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Serious adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence and severity of serious adverse events and suspected unrelated serious adverse events 12 months follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CSCC_ASC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSCC_ASC</intervention_name>
    <description>The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)</description>
    <arm_group_label>CSCC_ASC</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cardiology Stem Cell Centre_adipose derived stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 30 to 80 years of age&#xD;
&#xD;
          2. Signed informed consent&#xD;
&#xD;
          3. Chronic stable ischemic heart disease&#xD;
&#xD;
          4. Symptomatic heart failure New York Heart Association (NYHA) class II-III&#xD;
&#xD;
          5. EF ≤ 45% on echocardiography, Computerized Tomography (CT) or Magnetic Resonances&#xD;
             Imaging (MRI) scan&#xD;
&#xD;
          6. Plasma NT-pro-BNP &gt; 300 pg/ml (&gt; 35 pmol/L)&#xD;
&#xD;
          7. Maximal tolerable heart failure medication&#xD;
&#xD;
          8. Heart failure medication unchanged two months prior to inclusion. Changes in diuretics&#xD;
             accepted.&#xD;
&#xD;
          9. No option for percutaneous coronary intervention (PCI) or coronary artery bypass graft&#xD;
             (CABG)&#xD;
&#xD;
         10. Patients who have had PCI or CABG within six months of inclusion must have a new&#xD;
             coronary angiography less than one month before inclusion or at least four months&#xD;
             after the intervention to rule out early restenosis&#xD;
&#xD;
         11. Patients cannot be included until three months after implantation of a cardiac&#xD;
             resynchronisation therapy device (CRTD) and until 1 month after an ICD unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Heart Failure (NYHA class I or IV)&#xD;
&#xD;
          2. Acute coronary syndrome with acute reversible elevation of CKMB or troponins, stroke&#xD;
             or transitory cerebral ischemia within six weeks of inclusion. Constant elevated&#xD;
             troponin due to renal failure, heart failure etc. do not exclude the patient.&#xD;
&#xD;
          3. Other revascularisation treatment within four months of treatment&#xD;
&#xD;
          4. If clinically indicated the patient should have a coronary angiography before&#xD;
             inclusion&#xD;
&#xD;
          5. Moderate to severe aortic stenosis (valve area &lt; 1.3 cm2) or valvular disease with&#xD;
             option for surgery or interventional therapy.&#xD;
&#xD;
          6. Aortic valve replacement with an artificial heart valve. However, a trans-septal&#xD;
             treatment approach can be considered in these patients.&#xD;
&#xD;
          7. If the patient is expected to be candidate for MitraClip therapy of mitral&#xD;
             regurgitation in the 12 months follow-up period.&#xD;
&#xD;
          8. Diminished functional capacity for other reasons such as: obstructive pulmonary&#xD;
             disease (COPD) with forced expiratory volume (FEV) &lt;1 L/min, moderate to severe&#xD;
             claudication or morbid obesity&#xD;
&#xD;
          9. Clinical significant anaemia (haemoglobin &lt; 6 mmol/L), leukopenia (leucocytes &lt; 2&#xD;
             109/L), leucocytosis (leucocytes &gt; 14 109/L) or thrombocytopenia (thrombocytes &lt; 50&#xD;
             109/L)&#xD;
&#xD;
         10. Reduced kidney function (estimated Glomerular Filtration Rate (eGFR) &lt; 30 ml/min)&#xD;
&#xD;
         11. Left ventricular thrombus&#xD;
&#xD;
         12. Anticoagulation treatment that cannot be paused during cell injections. Patients can&#xD;
             continue with platelet inhibitor treatment&#xD;
&#xD;
         13. Patients with reduced immune response or known anti-HLA (human leukocyte antigen)&#xD;
             antibodies&#xD;
&#xD;
         14. History with malignant disease within five years of inclusion or suspected malignity -&#xD;
             except treated skin cancer other than melanoma&#xD;
&#xD;
         15. Pregnant women&#xD;
&#xD;
         16. Other experimental treatment within four weeks of baseline tests&#xD;
&#xD;
         17. Participation in another intervention trial&#xD;
&#xD;
         18. Life expectancy less than one year&#xD;
&#xD;
         19. Known hypersensitivity to Dimethyl sulfoxide (DMSO), penicillin and streptomycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Kastrup, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>JKastrup</investigator_full_name>
    <investigator_title>MD Professor</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>stem cell</keyword>
  <keyword>adipose derived stem cell</keyword>
  <keyword>Stem cell therapy</keyword>
  <keyword>ischemic heart disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data can be shared for Scientific collaboration</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

